Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Receives Consensus Rating of “Moderate Buy” from Brokerages

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company.

A number of analysts recently commented on BIOVF shares. Danske lowered Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, February 19th. BNP Paribas Exane raised Swedish Orphan Biovitrum to an “outperform” rating in a research note on Tuesday, February 10th. Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, February 24th. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, May 7th. Finally, HC Wainwright began coverage on shares of Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They issued a “buy” rating for the company.

Swedish Orphan Biovitrum Price Performance

Swedish Orphan Biovitrum stock opened at $47.48 on Friday. The stock has a market capitalization of $16.90 billion, a price-to-earnings ratio of 158.25 and a beta of 0.34. Swedish Orphan Biovitrum has a 52-week low of $27.06 and a 52-week high of $47.48. The stock’s 50 day moving average price is $42.02 and its two-hundred day moving average price is $38.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.59 and a current ratio of 0.90.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.07. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 17.23%. The firm had revenue of $755.76 million during the quarter, compared to the consensus estimate of $749.76 million. On average, equities analysts predict that Swedish Orphan Biovitrum will post 2.26 earnings per share for the current year.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.